Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab

Bibliographische Detailangaben
Veröffentlicht in:	Clinical immunology (Orlando, Fla.). - 1999. - 215(2020) vom: 01. Juni, Seite 108428
1. Verfasser:	Pistillo, Maria Pia (VerfasserIn)
Weitere Verfasser:	Carosio, Roberta, Grillo, Federica, Fontana, Vincenzo, Mastracci, Luca, Morabito, Anna, Banelli, Barbara, Tanda, Enrica, Cecchi, Federica, Dozin, Beatrice, Gualco, Marina, Salvi, Sandra, Spagnolo, Francesco, Poggi, Alessandro, Queirolo, Paola
Format:	Online-Aufsatz
Sprache:	English
Veröffentlicht:	2020
Zugriff auf das übergeordnete Werk:	Clinical immunology (Orlando, Fla.)
Schlagworte:	Journal Article Research Support, Non-U.S. Gov't Best overall response CTLA-4 Immunohistochemistry Ipilimumab Melanoma TIL Antineoplastic Agents, Immunological Biomarkers mehr... CTLA-4 Antigen CTLA4 protein, human

Beschreibung
Zusammenfassung:	Copyright © 2020 Elsevier Inc. All rights reserved. The expression of the immune checkpoint molecule CTLA-4 has been almost exclusively studied in the T cell lineage, but increasing evidence has shown its expression on tumors with implications for immunotherapy. To date, the degree of expression of CTLA-4 on tumor cells as a predictive biomarker of response to immune checkpoint inhibitors has not been studied. In this report, we analyzed this issue in melanoma patients treated with CTLA-4 inhibitor Ipilimumab (IPI). We show that the level of CTLA-4 expression on melanoma cells is higher than that on tumor infiltrating lymphocytes (TIL) and it is associated with clinical response to IPI therapy supporting the idea of its possible role as a predictive biomarker
Beschreibung:	Date Completed 29.01.2021 Date Revised 29.01.2021 published: Print-Electronic Citation Status MEDLINE
ISSN:	1521-7035
DOI:	10.1016/j.clim.2020.108428